S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$62.62
-0.7%
$65.03
$44.27
$74.64
$1.40B0.87112,762 shs85,261 shs
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
$13.02
+0.2%
$13.78
$9.57
$21.60
$487.08M1.04410,863 shs383,693 shs
SI-BONE, Inc. stock logo
SIBN
SI-BONE
$15.30
+0.5%
$17.31
$14.84
$29.51
$628.22M1.2436,793 shs299,377 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$26.39
-0.5%
$29.54
$16.79
$39.41
$375.79M1.0157,953 shs140,406 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
-0.67%-4.63%-6.63%+8.62%+19.05%
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
+0.15%-6.67%-6.20%-3.63%-30.45%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
+0.46%-2.49%-5.26%-17.48%-29.56%
Surmodics, Inc. stock logo
SRDX
Surmodics
-0.49%-4.66%-5.04%-22.31%+12.11%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.7573 of 5 stars
1.33.03.30.01.73.32.5
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
0.5858 of 5 stars
2.01.00.00.01.71.71.3
SI-BONE, Inc. stock logo
SIBN
SI-BONE
4.2014 of 5 stars
4.52.00.03.31.72.50.6
Surmodics, Inc. stock logo
SRDX
Surmodics
4.1278 of 5 stars
3.52.00.03.42.41.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.67
Moderate Buy$68.208.91% Upside
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
2.00
Hold$15.5019.05% Upside
SI-BONE, Inc. stock logo
SIBN
SI-BONE
3.00
Buy$26.6774.29% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$59.00123.57% Upside

Current Analyst Ratings

Latest SIBN, LMAT, OFIX, and SRDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
4/3/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
3/28/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
3/7/2024
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $15.00
2/28/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$66.00 ➝ $69.00
2/27/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $26.00
2/27/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00
2/27/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $24.00
2/6/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Weight
2/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $47.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$193.48M7.22$1.74 per share35.91$13.38 per share4.68
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
$746.64M0.65N/AN/A$16.11 per share0.81
SI-BONE, Inc. stock logo
SIBN
SI-BONE
$138.89M4.52N/AN/A$4.18 per share3.66
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M2.83$0.78 per share33.92$8.48 per share3.11

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.3446.7334.412.7615.56%10.57%9.15%5/7/2024 (Estimated)
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
-$151.40M-$4.14N/AN/AN/A-20.28%-10.63%-7.34%5/14/2024 (Estimated)
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$43.34M-$1.14N/AN/AN/A-31.20%-28.22%-20.53%5/6/2024 (Confirmed)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.3869.45N/AN/A3.99%8.06%5.11%4/24/2024 (Estimated)

Latest SIBN, LMAT, OFIX, and SRDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$0.29N/A+$0.29N/AN/AN/A  
3/5/2024Q4 2023
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
-$0.60-$0.59+$0.01-$0.59N/A$200.42 million    
2/27/2024Q4 2023
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.36$0.38+$0.02$0.38$49.01 million$48.90 million    
2/26/2024Q4 2023
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$0.29-$0.27+$0.02-$0.27$38.60 million$38.86 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.641.02%+13.80%47.76%13 Years
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
N/AN/AN/AN/AN/A
SI-BONE, Inc. stock logo
SIBN
SI-BONE
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Latest SIBN, LMAT, OFIX, and SRDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.9%3/13/20243/14/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
6.51
4.57
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
0.19
2.54
1.20
SI-BONE, Inc. stock logo
SIBN
SI-BONE
0.21
9.01
8.15
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.84
3.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
89.76%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
98.11%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
12.40%
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
4.70%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
5.40%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
61422.30 million19.54 millionOptionable
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
1,63437.41 million35.65 millionOptionable
SI-BONE, Inc. stock logo
SIBN
SI-BONE
34441.06 million38.85 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.24 million12.97 millionOptionable

SIBN, LMAT, OFIX, and SRDX Headlines

SourceHeadline
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM
Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"
americanbankingnews.com - April 17 at 3:42 AM
Surmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.comSurmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.com
marketbeat.com - April 16 at 11:04 PM
Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three yearsInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three years
finance.yahoo.com - April 13 at 8:40 AM
Surmodics, Inc. to Post Q1 2025 Earnings of ($0.23) Per Share, Zacks Research Forecasts (NASDAQ:SRDX)Surmodics, Inc. to Post Q1 2025 Earnings of ($0.23) Per Share, Zacks Research Forecasts (NASDAQ:SRDX)
americanbankingnews.com - April 12 at 2:20 AM
Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 11 at 7:42 AM
Surmodics (SRDX) Buy Rating Reiterated at Needham & Company LLCSurmodics' (SRDX) Buy Rating Reiterated at Needham & Company LLC
americanbankingnews.com - April 11 at 5:24 AM
Surmodics, Inc. Expected to Earn Q4 2025 Earnings of $0.66 Per Share (NASDAQ:SRDX)Surmodics, Inc. Expected to Earn Q4 2025 Earnings of $0.66 Per Share (NASDAQ:SRDX)
americanbankingnews.com - April 11 at 1:48 AM
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
markets.businessinsider.com - April 10 at 4:59 PM
Surmodics (SRDX) "Buy" Rating Reiterated at Needham & Company LLCSurmodics' (SRDX) "Buy" Rating Reiterated at Needham & Company LLC
marketbeat.com - April 10 at 11:26 AM
Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 10 at 8:44 AM
New Strong Buy Stocks for April 9thNew Strong Buy Stocks for April 9th
zacks.com - April 9 at 7:16 AM
Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?
finance.yahoo.com - March 23 at 1:09 PM
Q2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by AnalystQ2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Analyst
marketbeat.com - March 22 at 7:50 AM
Brokers Offer Predictions for Surmodics, Inc.s Q4 2025 Earnings (NASDAQ:SRDX)Brokers Offer Predictions for Surmodics, Inc.'s Q4 2025 Earnings (NASDAQ:SRDX)
marketbeat.com - March 21 at 8:36 AM
Heres Why You Should Hold Surmodics (SRDX) Stock for NowHere's Why You Should Hold Surmodics (SRDX) Stock for Now
zacks.com - March 20 at 12:30 PM
Are Surmodics, Inc.s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?Are Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?
finance.yahoo.com - March 2 at 1:31 PM
Surmodics to Participate in Upcoming Investor Conferences in March and AprilSurmodics to Participate in Upcoming Investor Conferences in March and April
businesswire.com - February 27 at 8:00 AM
SYK Jun 2024 290.000 putSYK Jun 2024 290.000 put
ca.finance.yahoo.com - February 6 at 1:03 PM
Heres What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter Results
finance.yahoo.com - February 4 at 9:23 AM
Heres Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.s (NASDAQ:SRDX) CEO Pay PacketHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay Packet
finance.yahoo.com - February 2 at 5:33 PM
Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript
finance.yahoo.com - February 2 at 12:26 PM
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 ViewSurmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
finance.yahoo.com - February 2 at 12:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

LeMaitre Vascular logo

LeMaitre Vascular

NASDAQ:LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Orthofix Medical logo

Orthofix Medical

NASDAQ:OFIX
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
SI-BONE logo

SI-BONE

NASDAQ:SIBN
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.